{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:46Z","timestamp":1791111346571,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists Biologic Register Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/100015756","name":"Janssen Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Samsung Bioepsis"},{"name":"Psoriasis Association PhD studentship"},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Piel Sana of the Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda"},{"name":"Spanish Medicines and Health Products Agency"},{"DOI":"10.13039\/100020992","name":"French National Health Insurance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020992","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French National Agency for Medicines and Health Products Safety"},{"DOI":"10.13039\/501100009820","name":"Assistance Publique-H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002738","name":"AP-HP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The lack of evidence from routine clinical settings has limited the widespread adoption of adalimumab biosimilars for the treatment of psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the drug survival and safety of adalimumab biosimilars with Humira\u00ae in psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM). Adalimumab-na\u00efve patients initiating adalimumab biosimilars (new users) were compared with Humira new users. Patients switching from Humira to biosimilars (switchers) were compared with those who continued Humira treatment. Patients were matched 1 : 1 based on previous adalimumab exposure time to create equal-sized cohorts of biosimilar and Humira users. Co-primary outcomes included drug discontinuation and serious adverse events (SAEs). Hazard ratios (HRs) were calculated using Cox proportional hazard models. Meta-analyses using random-effect models were performed to combine results from the three databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 7387 biosimilar new users and 3654 switchers were matched and compared with Humira users. No differences in all-cause discontinuation were found between biosimilar and Humira new users [HR 0.99, 95% confidence interval (CI) 0.94\u20131.04]. Switching from Humira to biosimilars was associated with a higher discontinuation rate than remaining on Humira (HR 1.35, 95% CI 1.19\u20131.52). Similar results were observed for discontinuation due to ineffectiveness or adverse events. Risks of SAEs were similar between biosimilar new users and Humira new users [incidence rate ratio (IRR) 0.91, 95% CI 0.80\u20131.05] or between switchers and continuous Humira users (IRR 0.92, 95% CI 0.83\u20131.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adalimumab biosimilars can be considered viable alternatives to Humira for new patients, with comparable effectiveness and safety. However, owing to the higher likelihood of discontinuation, patients who switch from Humira to biosimilars may require closer monitoring and support.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae454","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T14:32:28Z","timestamp":1732113148000},"page":"641-652","source":"Crossref","is-referenced-by-count":5,"title":["Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a\u00a0multinational cohort study"],"prefix":"10.1093","volume":"192","author":[{"given":"Duc Binh","family":"Phan","sequence":"first","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR), Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Jourdain","sequence":"additional","affiliation":[{"name":"EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM) , Saint-Denis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Descalzo-Gallego","sequence":"additional","affiliation":[{"name":"Research Unit, Fundacion Piel Sana AEDV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonz\u00e1lez-Quesada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM) , Saint-Denis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario y Politecnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Versus Arthritis Epidemiology Unit, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-5260","authenticated-orcid":false,"given":"Ignacio","family":"Garcia-Doval","sequence":"additional","affiliation":[{"name":"Research Unit, Fundacion Piel Sana AEDV , Madrid ,","place":["Spain"]},{"name":"Department of Dermatology, Complexo Hospitalario Universitario de Vigo , Vigo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM) , Saint-Denis ,","place":["France"]},{"name":"EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, Paris Est Cr\u00e9teil University, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR), Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR), Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025031819355396400_ljae454-B1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025031819355396400_ljae454-B2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjd.13908","article-title":"Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register","volume":"173","author":"Iskandar","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B3","doi-asserted-by":"crossref","first-page":"e2244670","DOI":"10.1001\/jamanetworkopen.2022.44670","article-title":"Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland","volume":"5","author":"Carl","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025031819355396400_ljae454-B4","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","article-title":"Overview of Humira\u00ae biosimilars: current European landscape and future implications","volume":"110","author":"Coghlan","year":"2021","journal-title":"J Pharm Sci"},{"key":"2025031819355396400_ljae454-B5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/bjd\/ljad107","article-title":"Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"189","author":"Phan","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B6","doi-asserted-by":"crossref","first-page":"19569","DOI":"10.1038\/s41598-022-24050-7","article-title":"TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System","volume":"12","author":"Jourdain","year":"2022","journal-title":"Sci Rep"},{"key":"2025031819355396400_ljae454-B7","first-page":"102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2025031819355396400_ljae454-B8","doi-asserted-by":"crossref","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians\u2019 perceptions of the uptake of biosimilars: a systematic review","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"key":"2025031819355396400_ljae454-B9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","article-title":"The language of biosimilars: clarification, definitions, and regulatory aspects","volume":"77","author":"Declerck","year":"2017","journal-title":"Drugs"},{"key":"2025031819355396400_ljae454-B10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/jpgm.JPGM_109_19","article-title":"Pharmacovigilance of biosimilars \u2013 why is it different from generics and innovator biologics?","volume":"65","author":"Oza","year":"2019","journal-title":"J Postgrad Med"},{"key":"2025031819355396400_ljae454-B11","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211031420","article-title":"A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study","volume":"14","author":"Barberio","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025031819355396400_ljae454-B12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/apt.17525","article-title":"Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: the ADA-SWITCH study","volume":"58","author":"Casanova","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025031819355396400_ljae454-B13","doi-asserted-by":"crossref","first-page":"989514","DOI":"10.3389\/fmed.2022.989514","article-title":"Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: results of a retrospective French multicenter study","volume":"9","author":"Larid","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025031819355396400_ljae454-B14","article-title":"Comparison of efficacy and safety of original and biosimilar adalimumab in active rheumatoid arthritis in a real-world national cohort","volume":"58","author":"Popescu","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2025031819355396400_ljae454-B15","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","article-title":"Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden","volume":"61","author":"Di Giuseppe","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025031819355396400_ljae454-B16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102522","article-title":"Adalimumab originator vs. biosimilar in hidradenitis suppurativa: a multicentric retrospective study","volume":"10","author":"Burlando","year":"2022","journal-title":"Biomedicines"},{"key":"2025031819355396400_ljae454-B17","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1111\/jdv.18801","article-title":"Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: can equivalence be assumed? A retrospective cohort study","volume":"37","author":"Grau-P\u00e9rez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031819355396400_ljae454-B18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025031819355396400_ljae454-B19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025031819355396400_ljae454-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2025031819355396400_ljae454-B21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025031819355396400_ljae454-B22","doi-asserted-by":"crossref","first-page":"e075197","DOI":"10.1136\/bmjopen-2023-075197","article-title":"Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study","volume":"13","author":"Phan","year":"2023","journal-title":"BMJ Open"},{"key":"2025031819355396400_ljae454-B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025031819355396400_ljae454-B24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Garcia-Doval","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B25","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.lanepe.2021.100158","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"Suppl. 4","key":"2025031819355396400_ljae454-B26","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2025031819355396400_ljae454-B27","doi-asserted-by":"crossref","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"key":"2025031819355396400_ljae454-B28","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"2025031819355396400_ljae454-B29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025031819355396400_ljae454-B30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2025031819355396400_ljae454-B31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogov\u00e1","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B33","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025031819355396400_ljae454-B34","doi-asserted-by":"crossref","first-page":"625296","DOI":"10.3389\/fphar.2021.625296","article-title":"Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure","volume":"12","author":"Vogler","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025031819355396400_ljae454-B35","doi-asserted-by":"crossref","first-page":"e00208","DOI":"10.1002\/prp2.208","article-title":"The nocebo effect of drugs","volume":"4","author":"Plan\u00e8s","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"2025031819355396400_ljae454-B36","doi-asserted-by":"crossref","first-page":"e050949","DOI":"10.1136\/bmjopen-2021-050949","article-title":"Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients\u2019 satisfaction: a cross-sectional survey by patient organisations","volume":"12","author":"Kayoko","year":"2022","journal-title":"BMJ Open"},{"key":"2025031819355396400_ljae454-B37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/acr2.11634","article-title":"Rheumatology patients\u2019 experiences of a mandatory nationwide transition to an adalimumab biosimilar","volume":"6","author":"Gasteiger","year":"2024","journal-title":"ACR Open Rheumatology"},{"key":"2025031819355396400_ljae454-B38","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041007","article-title":"Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa","volume":"11","author":"Montero-Vilchez","year":"2022","journal-title":"J Clin Med"},{"key":"2025031819355396400_ljae454-B39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-022-00526-w","article-title":"Outcomes following adalimumab bio-originator to biosimilar switch \u2013 a comparison using real-world patient- and physician-reported data in European countries","volume":"10","author":"Taylor","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025031819355396400_ljae454-B40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ad.2020.05.008","article-title":"Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the Spanish Biobadaderm registry","volume":"111","author":"Ruiz-Genao","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae454\/60766168\/ljae454.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/641\/60766168\/ljae454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/641\/60766168\/ljae454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:36:19Z","timestamp":1742326579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/4\/641\/7905298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae454","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,20]]}}}